Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
22 Results for "
GPR17
" in MedChemExpress (MCE) Product Catalog:
Products (22)
22 Results for "GPR17" in MCE Product Catalog:
4
Target:
Research Areas:
Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .
Target:
Research Areas:
P2Y2R/GPR17 antagonist 1 (Compound 14m) is a dual P2Y2R and GPR17 antagonist with IC50 values of 3.17 µM and 1.67 µM against P2Y2R and GPR17, respectively. P2Y2R/GPR17 antagonist 1 shows excellent metabolic stability in human liver microsomes .
Cat. No.: HY-170589
CAS No.: 1574405-61-0
Target:
Research Areas:
GPR17 antagonist 1 (compound 978) is a GPR17 antagonist. GPR17 antagonist 1 can be used in the study of diabetes and obesity .
Cat. No.: HY-19638
CAS No.: 163706-06-7
Synonyms: AR-C69931MX
Target:
Research Areas:
Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist .
Cat. No.: HY-164311
CAS No.: 3039853-91-0
Target:
Research Areas:
GPR17 modulator-1 (Compound 2-046) is a modulator for G protein-coupled receptor 17 GPR17, with an IC50<10 nM for hGPR17 in CHO. GPR17 modulator-1 exhibits moderate pharmacokinetic characteristics in mice. GPR17 modulator-1 ix blood-brain barrier (BBB) permeable .
Target:
Research Areas:
ASN04885796 (compound IV) is an GPR17 activator with an EC50 of 2.27 nM for GPR17 induced GTPγS binding. ASN04885796 has neuroprotective property and can be used for research of neurological diseases .
Target:
Research Areas:
ASN06917370 is a former orphan receptor GPR17 ligand for the study of neurodegenerative diseases. ASN06917370 has an EC50 of 268 pM in [35S]GTPyS experiments .
Target:
Research Areas:
ASN02563583, a compound that regulates the activity of the GPR17 receptor, has a IC50 value of 0.64 nM in [35S]GTPγS binding assay. ASN02563583 can be used in the study of neurological diseases .
Cat. No.: HY-RS05679
Target:
Research Areas:
GPR17 Human Pre-designed siRNA Set A contains three designed siRNAs for GPR17 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-181738
Target:
Research Areas:
GPR17 agonist 2 (compound 10) is a human GPR17 agonist and selective P2Y receptor non-activator.GPR17 agonist 2 modulates intracellular cAMP levels through functional activation of its target receptor.GPR17 agonist 2 can be used for the research of multiple sclerosis, cerebral ischemia, traumatic brain injury, spinal cord injury .
Cat. No.: HY-125313
CAS No.: 139896-80-3
Target:
Research Areas:
PSB-1737 is a human-selective GPR17 agonist with an EC50 for human GPR17 of 270 nM, and its activity on murine GPR17 is relatively weak (EC50 > 10 μM). PSB-1737 shows no significant inhibition at the glycine binding site of NMDA receptors, and has no significant agonistic or antagonistic activity on P2Y receptor subtypes. PSB-1737 can be used in demyelinating diseases (such as multiple sclerosis) or inflammatory-related anemia .
Cat. No.: HY-RS17462
Target:
Research Areas:
Gpr17 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Gpr17 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS23920
Target:
Research Areas:
Gpr17 Rat Pre-designed siRNA Set A contains three designed siRNAs for Gpr17 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-19638AR
CAS No.: 163706-36-3
Synonyms: AR-C69931MX tetrasodium (Standard)
Target:
Research Areas:
Cangrelor (tetrasodium) (Standard) is the analytical standard of Cangrelor (tetrasodium). This product is intended for research and analytical applications. Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
ASN04421891 is a GPR17 agonist with nanomolar EC50 and high specificity. ASN04421891 promotes oligodendrocyte precursor cell maturation to mature myelinating oligodendrocytes. ASN04421891 can be used for the research of cerebral ischaemia, cardiac ischaemia, renal ischaemia, cerebral trauma, multiple sclerosis, schizophrenia, depression, alzheimer's disease, alzheimer-like dementia, parkinson's disease, huntington's chorea, amyotrophic lateral sclerosis (ALS), neuroinflammatory disorders .
Cat. No.: HY-159920
Target:
Research Areas:
PSB-22269 is a GPR17 antagonist with a Ki value of 8.91 nM. PSB-22269 further demonstrated significant inhibitory effects in cAMP and G protein activation assays. Molecular docking studies revealed that the binding site of PSB-22269 contains positively charged arginine residues and a hydrophobic pocket. PSB-22269 provides a strategy to promote remyelination and holds promise for research in the field of multiple sclerosis .
Cat. No.: HY-182724
CAS No.: 2244978-64-9
Target:
Research Areas:
PSB-18422 is a GPR17 agonist, with an EC50 of 0.0279 μM for humans, 0.47 μM for rats, 0.753 μM for mice, and a human Ki of 1.46 μM. PSB-18422 triggers intracellular calcium mobilization via cross-species activation of GPR17. PSB-18422 can be used in the research of allergic bronchial inflammation .
Cat. No.: HY-179606
CAS No.: 2877694-62-5
Research Areas:
RWT9996 is a GPR17 antagonist. RWT9996 inhibits GPR17-mediated signal transduction processes, including G protein activation and β-arrestin-2 recruitment. RWT9996 inhibits MDL-29951 (HY-16312)-mediated phosphorylation of ERK1/2, phosphorylation of CREB, and accumulation of inositol phosphate (IP1) in oligodendrocyte precursor cells in vitro. RWT9996 can be used in studies related to demyelinating diseases .
Cat. No.: HY-P705954
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: GPR17; UDP/CysLT Receptor; G Protein-Coupled Receptor 17; P2Y-Like Receptor; Uracil Nucleotide/Cysteinyl Leukotriene Receptor; R12; G-Protein Coupled Receptor 17
Species:
Source:
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
